Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...